KG-501 (Naphthol AS-E phosphate)
(Synonyms: 色酚AS-E磷酸盐,Naphthol AS-E phosphate) 目录号 : GC31654
KG-501 (Naphthol AS-E phosphate) 是一种能够抑制cAMP反应元件结合蛋白（CREB）与CREB结合蛋白（CBP）相互作用的小分子化合物，其IC₅₀值为6.89μM。
Cas No.:18228-17-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
KG-501 (Naphthol AS-E phosphate) is a small molecule compound that can inhibit the interaction between cAMP response element-binding protein (CREB) and CREB-binding protein (CBP), with an IC₅₀ value of 6.89μM[1]. KG-501 directly targets the KIX domain of CBP to disrupt the binding of phosphorylated CREB (Ser-133) to KIX (Kᵢ ≈ 90μM), thereby inhibiting the transcriptional activity of cAMP-related genes[2]. KG-501 can inhibit the expression of endogenous CREB target genes (NR4A2, c-fos) induced by forskolin in cellular models and promote the recovery of neural function[3]. KG-501 can also inhibit IL-1β-mediated CXC chemokine expression and angiogenic activity in non-small cell lung cancer[4].
In vitro, pre-treatment of C2C12 myoblasts with KG-501 (250μM) for 30 minutes to 2 hours, followed by stimulation with IFN-γ (60ng/ml) for 72 hours, significantly inhibits the mRNA accumulation of CREB pathway molecules (CREB1, Bcl-xl, MEF-2) and the protein expression level of p-CREB1, while reducing the gene expression of inflammation-related cytokines (IL-1β, IL-6, TNF-α) and chemokines (MIP-1α, MCP-1)[5]. Pre-treatment of the human colorectal cancer cell line SW480 with KG-501 (5–25μM) for 24 hours significantly inhibits cell migration and invasion capabilities, while reducing the transcriptional and enzymatic activities of matrix metalloproteinases (MMP-2/MMP-9)[6].
In vivo, intracerebroventricular infusion of KG-501 (10–50μM; 3-5μL) in C57BL/6 mice for 3 days, followed by a single intraperitoneal injection of azoxymethane (AOM, 100mg/kg) to induce acute liver failure and hepatic encephalopathy, significantly accelerates AOM-induced neurofunctional decline (manifested as decreased neuroscore and shortened coma time), while inhibiting CREB protein expression, CCL2 inflammatory factor release, and ERK phosphorylation levels in the cortex, and reducing cAMP concentrations[7].
References:
[1] Lee JW, Park HS, Park SA, et al. A Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum Stress. PLoS One. 2015 Apr 21;10(4):e0122628.
[2] Best JL, Amezcua CA, Mayr B, et al. Identification of small-molecule antagonists that inhibit an activator: coactivator interaction. Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17622-7.
[3] Chiu SP, Wu MJ, Chen PY, et al. Neurotrophic action of 5-hydroxylated polymethoxyflavones: 5-demethylnobiletin and gardenin A stimulate neuritogenesis in PC12 cells. J Agric Food Chem. 2013 Oct 2;61(39):9453-63.
[4] Sun H, Chung WC, Ryu SH, et al. Cyclic AMP-responsive element binding protein- and nuclear factor-kappaB-regulated CXC chemokine gene expression in lung carcinogenesis. Cancer Prev Res (Phila). 2008 Oct;1(5):316-28.
[5] Gu R, Ding M, Shi D, et al. Calcium/Calmodulin-Dependent Protein Kinase IV Mediates IFN-γ-Induced Immune Behaviors in Skeletal Muscle Cells. Cell Physiol Biochem. 2018;46(1):351-364.
[6] Steven A, Heiduk M, Recktenwald CV, et al. Colorectal Carcinogenesis: Connecting K-RAS-Induced Transformation and CREB Activity In Vitro and In Vivo. Mol Cancer Res. 2015 Aug;13(8):1248-62.
[7] Woo JT, Yamaguchi K, Hayama T, et al. Suppressive effect of N-(benzyloxycarbonyl)-L-phenylalanyl-L-tyrosinal on bone resorption in vitro and in vivo. Eur J Pharmacol. 1996 Apr 4;300(1-2):131-5.
KG-501 (Naphthol AS-E phosphate) 是一种能够抑制cAMP反应元件结合蛋白（CREB）与CREB结合蛋白（CBP）相互作用的小分子化合物，其IC₅₀值为6.89μM[1]。KG-501通过直接靶向CBP的KIX结构域，破坏磷酸化CREB（Ser-133）与KIX的结合（Kᵢ ≈ 90μM），从而抑制cAMP相关基因的转录活性[2]。KG-501在细胞模型中能够抑制由佛司可林诱导的内源性CREB靶基因（NR4A2、c-fos）的表达，促进神经功能恢复[3]。KG-501还可抑制非小细胞肺癌中IL-1β介导的CXC趋化因子表达及血管生成活性[4]。
在体外，KG-501（250μM）预处理C2C12成肌细胞30分钟至2小时，随后以IFN-γ（60ng/ml）刺激72小时，显著抑制CREB通路分子（CREB1、Bcl-xl、MEF-2）的mRNA积累及p-CREB1蛋白表达水平，同时降低炎症相关细胞因子（IL-1β、IL-6、TNF-α）和趋化因子（MIP-1α、MCP-1）的基因表达[5]。KG-501（5–25μM）预处理人结肠癌细胞系SW480细胞24小时，显著抑制细胞迁移和侵袭能力，同时降低基质金属蛋白酶（MMP-2/MMP-9）的转录活性及酶活性[6]。
在体内，KG-501（10–50μM；3-5μL）通过侧脑室灌注预处理C57BL/6小鼠3天，随后以偶氮甲烷（AOM，100mg/kg）单次腹腔注射诱导急性肝衰竭及肝性脑病。KG-501显著加速AOM诱导的神经功能衰退（表现为神经评分下降及昏迷时间缩短），同时抑制皮层中CREB蛋白表达、CCL2炎性因子释放及ERK磷酸化水平，并降低cAMP浓度[7]。
| Cell experiment [1]: | |
Cell lines | SW480 (human colorectal carcinoma cell lines) |
Preparation Method | Cells were cultured in standard conditions (DMEM with 10% FBS at 37°C, 5% CO₂). For migration/invasion assays, cells were treated with KG-501(5–25μM; 24h). |
Reaction Conditions | 5–25μM; 24h |
Applications | KG-501 caused a strong, dose-dependent inhibition of cell migration and invasion in SW480. |
| Animal experiment [2]: | |
Animal models | C57BL/6 mice |
Preparation Method | Hepatic encephalopathy (HE) was induced by a single intraperitoneal (i.p.) injection of azoxymethane (AOM, 100mg/kg). Mice received an intracerebroventricular (i.c.v.) infusion of KG-501 (10, 20, or 50μM; 3-5μL) or vehicle (DMSO) 3 days prior to AOM injection. Neurological function was assessed by scoring reflexes (pinna, corneal, tail flexion, etc.), and the time to coma (loss of all reflexes) was recorded. Cortex tissues were collected at coma for analysis. |
Dosage form | 10, 20, or 50μM; 3-5μL; i.c.v. infusion |
Applications | KG-501 pretreatment significantly hastened neurological decline and shortened the time to coma in AOM-treated mice. KG-501 reduced cortical levels of CREB and the proinflammatory chemokine CCL2, and inhibited the phosphorylation of ERK and lowered cAMP concentration in the cortex, demonstrating that inhibition of CREB activity exacerbates HE by disrupting the protective cAMP/ERK signaling pathway. |
References: | |
| Cas No. | 18228-17-6 | SDF | |
| 别名 | 色酚AS-E磷酸盐,Naphthol AS-E phosphate | ||
| Canonical SMILES | O=C(C1=C(OP(O)(O)=O)C=C2C=CC=CC2=C1)NC3=CC=C(Cl)C=C3 | ||
| 分子式 | C17H13ClNO5P | 分子量 | 377.72 |
| 溶解度 | DMSO : 6 mg/mL (15.88 mM);Water : < 0.1 mg/mL (insoluble) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6475 mL | 13.2373 mL | 26.4746 mL |
| 5 mM | 529.5 μL | 2.6475 mL | 5.2949 mL |
| 10 mM | 264.7 μL | 1.3237 mL | 2.6475 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet